Safe use of intravesical bacillus Calmette-Guérin immunotherapy for bladder cancer during breastfeeding: a case report.

It is unknown whether intravesical bacillus Calmette-Guérin (BCG) is excreted in human breast milk. The US FDA advocates ceasing nursing due to potential adverse reactions. A lactating woman with bladder cancer who elected to receive intravesical immunotherapy with BCG and denied having ceased nursing her newborn is reported. A 42-year-old woman presented with macroscopic hematuria in the 36th week of her pregnancy. Imaging revealed a mass in the bladder. Cystoscopy and resection were performed after childbirth. Pathological examination revealed pT1 urothelial carcinoma. After a thorough discussion of the treatment options, the patient elected intravesical BCG. The infant received intradermal BCG vaccination 2 weeks before the treatment. As a result, the patient could breastfeed without any inadvertent sequela on herself or the baby.

Bacillus Calmette-Guérin (BCG) is tuberculosis vaccine. It contains live but attenuated tubercle bacillus. It is also used for bladder cancer treatment, where it is directly instilled into the bladder. BCG activates the local immune response within the bladder to fight cancer cells. The issue of whether BCG instillations into the bladder cause the bacillus to be excreted in breast milk in a lactating woman remains unknown. The US FDA suggests discontinuing breastfeeding when undergoing treatment with BCG due to potential adverse reactions. The authors report on a breastfeeding woman with bladder cancer who elected to receive BCG immunotherapy. The baby received a precautionary dermal BCG vaccination 2 weeks before the patient's treatment. Ultimately, she was able to complete her treatment while breastfeeding her child without any negative effects on the infant or herself. To the best of the authors' knowledge, this is the first article showing that breastfeeding may be safe during BCG treatment for bladder cancer.

Pediatric Minor Head Trauma: Factors Affecting the Anxiety of Parents.

Managing the anxiety of the parents of pediatric patients with head trauma is challenging. This study aimed to examine the factors that affect anxiety levels of parents whose children were admitted to the emergency department with minor head trauma. In this prospective study, the parents of 663 consecutive pediatric patients were invited to answer a questionnaire. Parents of 600 children participated in the study. The parents who believed they were provided sufficient information and who were satisfied with the service received had significantly more improvement in anxiety-related questions. Cranial X-ray assessment had a significantly positive impact on the anxiety of the parents, whereas cranial computed tomography and neurosurgery consultation did not. In assessing pediatric minor head trauma, cranial computed tomography imaging and neurosurgery consultation should not be expected to relieve the anxiety of the parents. However, adequately informing them and providing satisfaction are the factors that could lead to improvement.

Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection.

Advancements in medicine have enabled the use of monoclonal antibodies in the field of oncology. However, the new adverse effects of immunotherapeutic agents are still being reported. We present the first case of pembrolizumab-induced fatal colitis with concurrent Giardia infection in a patient with metastatic ovarian cancer. A 47-year-old woman with metastatic ovarian cancer who was being treated with pembrolizumab admitted to our clinic complaining of persisting bloody diarrhoea. Her stool antigen test was positive for Giardia. The patient received metronidazole. A colonoscopy with mucosal biopsy was performed upon no clinical or laboratory improvement. Colonoscopy detected deep exudative ulcers in sigmoid colon and rectum. The cytopathological evaluation revealed immune-mediated ischemic colitis. The treatment was rearranged with methylprednisolone. Upon an increase in bloody diarrhoea frequency and C-reactive protein levels, infliximab was started. However, the patient became refractory to infliximab therapy after the second dose and was deceased due to septic shock.

Endoscopic ultrasound-guided liver biopsy using a 20-gauge fine needle biopsy needle with the wet-heparinized suction technique.

OBJECTIVES: The primary aim of this study was to evaluate the histological adequacy of the liver tissue specimens obtained with a 20-gauge fine-needle biopsy needle and the secondary aim was to test the safety endoscopic ultrasound-guided liver biopsy with a 20-gauge fine-needle biopsy needle with the wet-heparinized suction technique. METHODS: Forty patients who underwent endoscopic ultrasound-guided liver biopsy were included in the study. A 20-gauge fine-needle biopsy needle was used with the wet-heparinized suction technique to make one pass each from the left and the right lobe. Histologic characteristics of the specimens were evaluated, and patients were observed after the procedure in order to intervene in case of an adverse event. RESULTS: The median longest core fragment was 22 mm from the left lobe [first quartile-third quartile 20-25 mm, interquartile range (IQR) 5 mm], and 20 mm (first quartile-third quartile 17-22 mm, IQR 5 mm) from the right lobe. The median cumulative core length per patient was 103 mm (91-108 mm, IQR 17 mm). The median cumulative number of complete portal triads per patient was 69.50 (52.25-82.25, IQR 30). The rate of diagnostic yield was 100%. Post-biopsy self-limiting abdominal pain was reported in two patients (5%). The most common histologic diagnosis was fatty liver disease (25%). CONCLUSION: Endoscopic ultrasound-guided liver biopsy with the wet-heparinized suction technique using a 20-gauge fine-needle biopsy needle is a safe alternative method in clinical practice.